Pharma-Cooperation-Code: Disclosure 2018

The signatory companies of the PCC have disclosed the following amounts regarding the pecuniary benefits granted in 2017:

• Approximately CHF 12.5 million to professionals
• Just over CHF 91 million to healthcare organizations
• Approximately CHF 59 million for R&D purposes
• Total amount of just over CHF 162.5 million

Again, there has been a slightly positive development regarding the part of the benefits disclosed naming the recipients individually. The industry aims at further increasing these values in order to continuously enhancing the degree of transparency of these cooperation payments.

The Responsible Care Programme: our commitment to sustainability

Responsible Care is the global chemical-pharmaceutical industry's unifying commitment to the safe management of chemicals throughout their life cycle, while promoting their role in improving quality of life and contributing to sustainable development. Your Website for Science and Technology